A new international study has mapped a type of immune cell, the microglia, in the human and mouse brain for the first time. Microglia are thought to play a role in the progression of MS. This research has changed the understanding of how these cells function, and has important implications for MS.
New study shows that early use of high efficacy treatment for MS improves long term disability outcomes, rather than starting on a moderately effective therapy and escalating to a stronger medication.
In a recent study, scientists have shown that people with MS who have food allergies are more likely to experience clinical attacks and lesions in the brain than those without allergies or with other allergies that are unrelated to food.
MSIF’s Atlas of MS with new data on the number of people living with MS across the world, and the challenges they face.
Driving global change - progress made by the global MSIF movement
976 chemicals were screened to assess their impact on MS.
A trial has compared a cancer chemotherapy to MS treatments, but further research is needed to understand how effective the treatment is in comparison to other MS treatments.
Studies show that improved MS medications and advances in MRI technology have led to an increased rate of doctors changing courses of MS treatment and a reduced tolerance of any sign of disease activity, with doctors more readily switching treatments in cases of low disease activity.
MSIF is pleased to announce the winner of this year’s Young Investigators Award: Dr Silke Häusser-Kinzel.
MSIF is proud to announce the recipients of the 2018 McDonald fellowships and Du Pre grants